Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
Prospective sequencing of samples provided new genetic information for 24.8 percent of patients, which changed risk category for 16.2 percent.
A single-arm, phase 2 trial was conducted to assess response to treatment with carfilzomib plus cyclophosphamide and dexamethasone among patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether CAR-T therapy would be an effective treatment for patients with relapsed/refractory multiple myeloma.
Semistructured interviews of patients and clinicians were conducted to explore how this disease affects the day-to-day lives of patients.
Ways to improve representation of African Americans in clinical trials could be extrapolated to other underrepresented groups.
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
Progression-free, three-year overall survival similar for lenalidomide maintenance regimen without dexamethasone.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
The approval was based on data from the multicenter, single-arm phase 2 HORIZON trial.
Researchers sought to determine if selinexor, bortezomib, and dexamethasone would give better responses over doublet therapy for patients with multiple myeloma.
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
The phase 2 MagnetisMM-3 trial will test the safety and efficacy of subcutaneous elranatamab (PF-06863135) for relapsed or refractory multiple myeloma.
Cartesian Therapeutics launches a trial of Descartes-11, which is designed to express CAR-T molecules transiently.
This exploratory analysis included data from the phase 3 POLLUX and CASTOR studies, which represent the largest set of minimal residual disease (MRD) data prospectively collected among patients with relapsed/refractory multiple myeloma.
Analysts checked patients’ health-related quality of life after adding daratumumab to bortezomib and dexamethasone used to treat relapse/refractory multiple myeloma.
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Risk for disease progression or death increased for those with renal insufficiency in relapsed/refractory, newly diagnosed MM
Investigators compared elotuzumab plus lenalidomide, bortezomib, and dexamethasone (RVd) with RVd alone in the induction and maintenance therapy settings.
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
Study results suggest that the cost-effectiveness of daratumumab use may be lower with first- vs second-line therapy of transplant-ineligible multiple myeloma.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Several biomarkers were predictive of progression from smoldering MM to MM, according to a retrospective study.
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Combined with dexamethasone, melflufen may be efficacious among patients with heavily pretreated relapsed and refractory multiple myeloma.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
Age, high-risk disease, renal disease, and active or progressive disease were predictive of worse outcomes for patients with multiple myeloma and COVID-19.
Currently, interpretations of FDG-PET/CT findings within the context of treatment response have not been validated in the setting of multiple myeloma.
Intermittent dosing of the targeted agent may overcome toxicity limitations, providing a potential therapy for a hard-to-treat multiple myeloma.
In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
Combination venetoclax, bortezomib, and dexamethasone may improve response rates among patients with relapsed/refractory MM with specific biomarkers.
A novel scoring system for patients with MM undergoing upfront autologous HSCT appears predictive of both progression-free survival and overall survival.
Adverse effect management and adherence strategies used to support patients with relapsed/refractory MM undergoing treatment on the STORM trial.
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
The triplet regimen resulted in an 18% reduction in risk for death.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.